Volume 19 Issue 2, June 2025

In conversation with Eric Esser, President and Chief Executive Officer, Telesis Bio

By detecting and targeting myeloid-dependent immune suppression, Bectas Therapeutics is on a mission to realize the full potential of cancer immunotherapies.

PROVIREX is developing first-in-class advanced therapies that may offer the chance of a cure for people with life-threatening persistent viral infections.

Bio-Sourcing is developing innovative solutions that combine cutting-edge gene-editing and nuclear-transfer technologies to up-scale the production of biopharmaceuticals while lowering carbon emissions and costs.

The clinical success of biologics is often hindered by a lack of safe, targeted delivery systems. SiVEC Biotechnologies aims to change this with its groundbreaking BactPac platform.

While the pace of dealmaking in the infectious diseases field has declined considerably from its peak during the COVID-19 pandemic, leading vaccine companies have still been signing major deals.

Combined Therapeutics’ proprietary messenger RNA multi-organ protection platform can encode antigens and adjuvants alike with high tissue specificity for better efficacy and safety profiles.

Over the past year, AI-focused biopharma collaborations have increasingly attracted large upfront payments and extended their reach outside of small molecule drug discovery.

Automating, harmonizing, accelerating, and democratizing multi-omics data analysis across industries.

Using its innovative SAFEPATH platform, which integrates cheminformatics and bioinformatics approaches, the AI-driven drug-turnaround company Ignota Labs is on a mission to understand the mechanisms of drug toxicity, rescue promising assets with previous safety issues, and get them to the clinic in record time.

SOPHiA GENETICS is untangling the multimodal complexities that have blunted the potential for artificial intelligence (AI)-driven analytics to accelerate drug development.

MultiOmic Health is using a data-driven AI-enabled approach to develop tailored therapeutics for specific subpopulations of patients with metabolic syndrome-related conditions, which affect around half of the adult population worldwide.

Causal artificial intelligence (AI) is transforming the pharma business model.

A review of upcoming drug launches, patent expiries, and pivotal trials, according to analysts at AdisInsight.

BioCanRx is leading the way in the translation, manufacture and adoption of immunotherapies in Canada to ensure that Canadian patients have access to this powerful therapeutic approach via clinical trials.

Induced pluripotent stem cell technology is a promising, rapidly evolving field with the potential to transform cell-based therapeutics across a range of disease areas that have significant unmet medical needs.

Poseidon Bio has developed an innovative modular technology platform based on an engineered human protein scaffold that can generate TCEs with a novel geometry to overcome the problems of current antibody-based immunotherapies.